Adamis Pharmaceuticals (ADMP) recently released a couple of positive updates regarding their SYMEPI and ZIMHI products. Despite both press releases being positive, the market smashed the share price down to fresh 52-week lows. Investors aren't biting on these updates and appear to be waiting for the stronger catalysts to act. In the absence of buyers, the shorts have been able to take advantage of the lack of interest in the ticker. Personally, I have been taking advantage of the short-sellers’ hard work and have added to my position. Despite the negative sentiment, the